Evidence map›Paper›PMID 26722418›Full record

ArticleInternational journal of clinical and experimental pathology2015

Expression and functional perspectives of miR-184 in pancreatic ductal adenocarcinoma.

He Li, Heping Xiang, Weiwei Ge, Hengtong Wang, Tianpeng Wang, Maoming Xiong

Open access · greenAbstract read
In one paragraph

Article in International journal of clinical and experimental pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

He LiDepartment of Emergency, The Second Affiliated Hospital of Anhui Medical University Hefei 230601, Anhui, China.
Heping XiangDepartment of Emergency, The Second Affiliated Hospital of Anhui Medical University Hefei 230601, Anhui, China.
Weiwei GeDepartment of Emergency, The Second Affiliated Hospital of Anhui Medical University Hefei 230601, Anhui, China.
Hengtong WangDepartment of Emergency, The Second Affiliated Hospital of Anhui Medical University Hefei 230601, Anhui, China.
Tianpeng WangDepartment of Emergency, The Second Affiliated Hospital of Anhui Medical University Hefei 230601, Anhui, China.
Maoming XiongDepartment of General Surgery, The First Affiliated Hospital of Anhui Medical University Hefei 230022, Anhui, China.
Anhui Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive malignant tumors, with its 5-year survival rate lower than 5%. MicroRNAs (miR) have been known as important regulators for the tumorigenesis, progression, invasion and metastasis of various cancers. MiR-184 was found to be abnormally expressed in various cancers including glioma and oral carcinoma. The expression and functional role of miR-184 in PDAC, however, remains unclear. PDAC cell line PANC-1 was transfected with miR-184 inhibitor. Real-time PCR was used to detect the expression of miR-184 in untreated PANC-1, miR-184 inhibitor transfected PANC-1 and controlled normal pancreatic ductal epithelial cell line HPDE6c7. MTT assay was used to detect the effect of miR-184 on the proliferation of PANC-1 cells, while invasion assay and Western blotting were employed to describe the effect on cell invasion ability and expression of caspase-3, respectively. In PANC-1 cells, miR-184 was abundantly expressed. The transfection of inhibitor effectively suppressed the expression of miR-184, and further inhibited both cell proliferation and invasion abilities, in addition to the up-regulation of pro-apoptotic protein caspase 3 expression. The up-regulation of miR-184 in PDAC may facilitate the proliferation and invasion ability, and inhibit apoptosis of tumor cells, thus potentiating the occurrence and development of PDAC. MiR-184, therefore, is a potential molecular target for therapy.

Indexed as

ApoptosisCarcinoma, Pancreatic DuctalCell Transformation, NeoplasticHumansMicroRNAsPancreasPancreatic NeoplasmsMicroRNAsMIRN184 microRNA, humanmicro RNA inhibitorPancreatic ductal adenocarcinomatumor proliferation and metastasis

Identifiers

PMID26722418
PMCPMC4680363
OpenAlexW2410555305

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.